The most profound shift in biology today isn’t a single discovery, but a fundamental change in methodology: the field is moving from being a purely empirical, experimental science to becoming a true engineering discipline. This transformation, powered by computational tools like AI and new biological platforms like CRISPR, is reshaping how we diagnose diseases, develop drugs, and even design living cells as intelligent therapies. At its core, this engineering mindset focuses on de-risking the traditional “science risk”—the unknown biological mechanisms—by applying repeatable, scalable processes, whether through algorithms that learn from genomic data or precise tools that edit genetic code with known functions.

This approach is already manifesting in powerful ways. In diagnostics, companies like Freenome use AI to interpret complex signals from blood samples to detect cancer early, turning massive genomic datasets into actionable health insights. In therapeutics, the focus has shifted to areas where the biology is well understood, such as sickle cell anemia, allowing engineers to apply tools like gene therapy to a clearly defined problem. This contrasts sharply with conditions like Alzheimer’s, where the root cause remains elusive and traditional drug development continues to face high failure rates. The engineering paradigm allows for building platforms—be it in mRNA, cell therapy, or AI-driven drug discovery—where success in one application can be systematically replicated for others, moving away from the bespoke, one-off nature of traditional biotech.

The conversation also delved into the practical pathways for these new “bio + tech” companies to reach the market. A common trajectory begins with demonstrating efficacy and engaging self-insured employers as early adopters, who value both cost savings and employee benefits. Successful companies then scale by moving to larger insurance plans and eventually to government programs like Medicare. Notably, as therapies become more targeted and effective—driven by engineering—the perceived regulatory risk diminishes, as seen with unanimous FDA panel votes for groundbreaking gene and cell therapies. The future promises even greater convergence, with the potential to design biological circuits inside cells and apply biology’s lessons to fields far beyond healthcare, from materials to data storage.

Surprising Insights

• Regulatory risk is often just scientific risk in disguise. When a therapeutic is highly effective because it targets a well-understood biological mechanism (like a specific genetic mutation), regulatory approval can be swift and unanimous, as seen with recent gene therapies.
• AI in biomedicine isn’t just about doing old things better; it enables the impossible. Machine learning can find patterns in biological data too complex for humans, leading to novel diagnostic tests and drug targets that were previously inconceivable.
• Data network effects create a moat that “never goes off patent.” Unlike traditional biotech, where patents provide temporary protection, a diagnostic company that improves its accuracy with every new data point creates a compounding, permanent barrier to entry for competitors.
• Clinical trial recruitment can be accelerated by 96% using social media. Partnerships like the one between Facebook and the Michael J. Fox Foundation demonstrate how tech platforms can dramatically reduce the time and cost of finding patients for studies.
• The most viable early customers for digital health are not insurance companies, but self-insured employers. They are more willing to adopt new products based on engagement and employee satisfaction before long-term cost-saving studies are complete.

Practical Takeaways

• For entrepreneurs, focus on de-risking the science. Build companies around biological mechanisms that are well-understood, and apply engineering to solve the delivery, scaling, or targeting challenge.
• Leverage data network effects for defensibility. Design business models where the product’s core value (e.g., diagnostic accuracy) improves inherently and automatically as more customers use it.
• Plan a go-to-market strategy that starts with self-insured employers. Use them as early adopters to prove engagement and efficacy, then use that evidence to navigate to larger insurance payers and, eventually, government programs.
• Seek founders who live at the intersection of disciplines. The most potent teams will have deep, credible expertise in both the biological domain and the engineering or computational tools they are applying.
• Think in platforms, not single products. Whether using AI on a genomic dataset or a CRISPR delivery system, design your core technology to be a repeatable engine for multiple applications to maximize scalability and value.